Mandate

Vinge has advised Hexatronic Group AB (publ) in connection with a directed share issue

November 09, 2021 Capital Markets and Public M&A

Vinge has advised Hexatronic Group AB (publ) in connection with a directed share issue whereby the company receives approximately SEK 550 million in gross issue proceeds.

The share issue was carried out as an accelerated book building process and directed to selected Swedish and international institutional investors. Hexatronic intends to use the net proceeds from the directed share issue to increase Hexatronics financial flexibility for further acquisitions, to establish a new plant for micro duct production in the US that will be up and running in Q3 2022, for investments in increased production capacity based on high demand mostly from growth markets, and for general corporate purposes to support growth opportunities. ABG Sundal Collier AB and Pareto Securities AB acted as joint bookrunners in connection with the directed share issue. Vinge acted as legal adviser to Hexatronic.

Hexatronic Group AB (publ) is a group that develops, markets and delivers products, components and system solutions with the main focus on the fiber optic market, and offers a wide range of innovative system and product solutions mainly for passive fiber optic infrastructure.

Vinge’s team has consisted of Anders Strid, Edin Agic and Adrian Filipovic.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026